Anand Mahindra to continue as M&M executive chairman till November next year

Anand Mahindra to continue as M&M executive chairman till November next year

PTIUpdated: Sunday, February 09, 2020, 08:39 AM IST
article-image
Anand Mahindra |

New Delhi: Mahindra & Mahindra on Saturday said Anand Mahindra has acceded the request of the board to continue as executive chairman till November next year.

The board of directors of the company have unanimously requested Anand Mahindra to continue as the executive chairman till his original term of appointment as approved by the shareholders of the company that is up to November 11, 2021, the company said in a BSE filing.

As per the SEBI guidelines, he had to step down from his executive role from April 1, 2020. "In deference to the wishes of the Governance, Nomination and Remuneration Committee (GNRC) and Board, Anand Mahindra has acceded to the request to continue as the Executive Chairman till his original term of appointment. Pawan Goenka and Anish Shah would continue to report to Anand Mahindra," it said. SEBI has deferred the deadline for compliance with Regulation 17 from April 1, 2020, to April 2022.

RECENT STORIES

OYO Assets Rakes In ₹ 125 Crore In Fresh Funding Round, Institutional & Private Investors Swarm...

OYO Assets Rakes In ₹ 125 Crore In  Fresh Funding Round, Institutional & Private Investors Swarm...

Finance Ministry Propels Historic Merger: Three Public Sector General Insurers To Fuse Into One...

Finance Ministry Propels Historic  Merger: Three Public Sector General Insurers To Fuse Into One...

Renewable Gas Worth ₹270 Crore Per Year Can Be Produced By Paddy Straw Burned By Farmers: Biogas...

Renewable Gas Worth ₹270 Crore Per Year Can Be Produced By Paddy Straw Burned By Farmers: Biogas...

Rolls-Royce Breaks Government Grip: Private Power Systems Demand To Lead India By 2026-27

Rolls-Royce Breaks Government Grip: Private Power Systems Demand To Lead India By 2026-27

Aurobindo Pharma Hit By Million Dollar Loss At China-Based Facility, Knocks Back With Growth...

Aurobindo Pharma Hit By Million Dollar Loss At China-Based Facility, Knocks Back With Growth...